Solventum Corporation (SOLV)
| Market Cap | 15.35B +29.1% |
| Revenue (ttm) | 8.16B -2.8% |
| Net Income | 156.00M -89.8% |
| EPS | 0.90 -89.7% |
| Shares Out | 169.96M |
| PE Ratio | 100.31 |
| Forward PE | 12.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,578,012 |
| Open | 86.45 |
| Previous Close | 87.18 |
| Day's Range | 85.05 - 93.10 |
| 52-Week Range | 62.38 - 94.16 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 94.69 (+4.85%) |
| Earnings Date | Nov 5, 2026 |
About SOLV
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tap... [Read more]
Financial Performance
In 2025, Solventum's revenue was $8.33 billion, an increase of 0.86% compared to the previous year's $8.25 billion. Earnings were $1.56 billion, an increase of 224.84%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for SOLV stock is "Buy." The 12-month stock price target is $94.69, which is an increase of 4.85% from the latest price.
News
Solventum price target raised to $100 from $95 at BTIG
BTIG raised the firm’s price target on Solventum (SOLV) to $100 from $95 and keeps a Buy rating on the shares. The company’s Q3 earnings topped estimates and its organic…
Solventum price target raised to $115 from $113 at Mizuho
Mizuho raised the firm’s price target on Solventum (SOLV) to $115 from $113 and keeps an Outperform rating on the shares.
Solventum price target raised to $110 from $105 at Piper Sandler
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $110 from $105 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results…
Solventum Earnings Call Transcript: Q3 2026
Q3 sales declined amid an ERP-related order reversal, while normalized organic growth was ~4% and margins improved YoY. FY2026 EPS guidance rose, and separation is more than 90% complete.
Solventum Slides: Q3 2026
Solventum has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Solventum Earnings release: Q3 2026
Solventum released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Solventum Quarterly report: Q3 2026
Solventum has published its Q3 2026 quarterly earnings report on November 5, 2026.
Solventum Shareholder letter: Q3 2026
Solventum has published a letter to shareholders covering Q3 2026, which was released on November 5, 2026.
Solventum reports Q3 adjusted EPS $1.45, consensus $1.35
Reports Q3 revenue $1.95B, consensus $1.94B.
Solventum sees FY26 adjusted EPS $7.20-$7.30, consensus $7.18
16:15 EST Solventum (SOLV) sees FY26 adjusted EPS $7.20-$7.30, consensus $7.18
Solventum Reports Third Quarter 2026 Financial Results
Reported sales decreased 7.0%; organic sales decreased 2.8%, reflecting the expected 630 basis point (bps) impact of prior quarter advance orders placed ahead of the planned ERP system cutover during ...
Solventum price target lowered to $35 from $38 at CIBC
CIBC lowered the firm’s price target on Solventum (SOLV) to $35 from $38 and keeps an Outperformer rating on the shares.
Solventum’s Restrata Matrix and Solventum V.A.C. Therapy receive FDA clearance
Solventum (SOLV) announced that the FDA has granted 510(k) clearance for the combined use of Restrata Synthetic Electrospun Fiber Matrix and Solventum V.A.C.( Therapy. Following Solventum’s acquisitio...
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes Clearance pairs innovative synthetic ele...
Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
EAGAN, Minn., Oct. 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2026 financial results on Thursday, November 5, 2026, after the U.S. financial markets close.
Solventum price target raised to $100 from $95 at BofA
BofA analyst Travis Steed raised the firm’s price target on Solventum (SOLV) to $100 from $95 and keeps a Neutral rating on the shares. The firm is updating its standalone…
Solventum collects initial bids for Health Information Systems unit, Axios says
Solventum (SOLV) is gathering initial bids for its Health Information Systems unit, Axios’ Brock Turner and Claire Rychlewski report. The business, which provides hospitals with medical coding, billin...
Solventum Transcript: Wells Fargo 21st Annual Healthcare Conference
Revised summary: Management confirmed the HIS separation is for strategic focus on medtech, with RemainCo’s 4%-5% organic growth target by 2028 intact. Margin dilution is expected, but operational efficiencies, new product launches, and growth in MedSurg and Dental support margin and EPS expansion. Nearly 20 new products are planned through Q1 2028.
Solventum management to meet with BTIG
Meeting to be held in Boston on September 10 hosted by BTIG.
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
Solventum price target raised to $105 from $92 at Piper Sandler
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $105 from $92 and keeps an Overweight rating on the shares following quarterly results. Quarterly execution vs. Street continues…
Solventum price target raised to $101 from $94 at Wedbush
Wedbush analyst Michael Piccolo raised the firm’s price target on Solventum (SOLV) to $101 from $94 and keeps an Outperform rating on the shares. The firm notes the company reported…
Solventum price target raised to $100 from $90 at Stifel
Stifel raised the firm’s price target on Solventum (SOLV) to $100 from $90 and keeps a Buy rating on the shares.
Solventum price target raised to $101 from $95 at UBS
UBS analyst Patrick Wood raised the firm’s price target on Solventum (SOLV) to $101 from $95 and keeps a Buy rating on the shares. Solventum delivered a strong Q2 with…
Solventum price target raised to $84 from $81 at BMO Capital
BMO Capital raised the firm’s price target on Solventum (SOLV) to $84 from $81 and keeps a Market Perform rating on the shares. The HIS separation could unlock value by…